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Abstract: Thymomas are rare epithelial tumors that display signif-
icant heterogeneity. Thymomas are usually indolent; however, thy-
mic carcinomas are typically invasive with a high risk of relapse and
death. Current treatment approaches are primarily based on clinical
stage. Surgery is the mainstay for treatment of early stage disease,
whereas multimodality therapy is required for advanced disease. The
most important prognostic factors are stage and histology; however,
increasing recognition of disease heterogeneity has led to recent
exploration of underlying molecular mechanisms. Molecular char-
acterization of thymic tumors may offer strategies to improve
diagnosis, therapy, and prognosis. This article describes recently
identified molecular characteristics of thymoma and thymic carci-
noma that may potentially impact disease classification, targeted
therapeutic decision making, and design of future clinical trials.
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Thymoma is a rare epithelial tumor, with an incidence of0.15 per 100,000 person-years.1 Thymic tumors are clas-
sified into types A, AB, B1, B2, B3, and C (thymic carci-
noma) according to the World Health Organization (WHO)
criteria based on morphology of epithelial cells with increas-
ing degree of atypia from type A to thymic carcinoma.2
Clinically, the most important prognostic indicator is thought
to be tumor stage (invasion of the capsule and tumor re-
sectibility).3 Recent molecular characterization of thymic
tumors includes identification of important oncogenes
(EGFR, HER2, KIT, KRAS, and BCL2), tumor suppressor
genes (TP53, p16INK4A), chromosomal aberrations (LOH 3p,
6p, 6q, 7p, 8p), angiogenic factors (vascular endothelial growth
factor [VEGF]), and tumor invasion factors (matrix metallopro-
teinases and tissue inhibitor of metalloproteinases); however,
these findings have yet to affect clinical practice.4
Molecular profiling analyses at the DNA level using
comparative genomic hybridization have confirmed a distinc-
tion between WHO types A to B2 versus type B3 and thymic
carcinomas.5–7 Furthermore, mRNA expression analysis us-
ing reverse-transcriptase polymerase chain reaction has iden-
tified two genes (c-JUN and AL050002 [an unknown gene])
at higher levels in advanced-stage thymomas.8 The biologic
significance of these findings remains to be determined.
Current treatment strategies are based on stage. Evi-
dence from prospective randomized trials is lacking. Contro-
versy exists in early and advanced disease and provides
impetus for a greater understanding of disease heterogeneity
through molecular characterization. Patients with stage I and
II disease are usually treated with surgery alone. Identifica-
tion of patients at high risk of local recurrence who require
postoperative radiation is controversial and only about 4% of
patients with stage II disease will recur postoperatively within
5 years.9 Patients with stage III and IV disease are offered
multimodality therapy with chemotherapy, surgery, and radi-
ation. The choice, timing, and sequencing of combined ther-
apy in stage III disease are unclear. Recurrent disease is
treated with surgery and radiation wherever possible; how-
ever, the optimal use of systemic therapy is controversial and
molecularly targeted agents remain experimental.
CHEMOTHERAPY AGENTS
Chemotherapy is offered to patients with advanced thy-
moma (stage III/IV) based on evidence from small phase II
studies in the context of upfront multimodality therapy and in the
setting of refractory or recurrent disease. The highest response
rates (70–81%) have been achieved with neoadjuvant cisplatin
and doxorubicin combination chemotherapy (Table 1).10–12
Nonanthracycline platinum-based combinations have demon-
strated inferior response rates (32–56%).13–15 Single-agent che-
motherapy is inferior to combined chemotherapy. Pemetrexed,
in a phase II study of patients with refractory thymoma, dem-
onstrated two complete responses (CRs) and two partial re-
sponses (PRs) of 23 evaluable patients (all four responders had
stage IVA thymoma).16
Predictors of response to chemotherapy are unclear.
The largest phase II trial to date of 44 patients treated with
carboplatin and paclitaxel confirmed different outcomes for
thymoma (n  23, median overall survival 60 months, 13%
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CR rate) and thymic carcinoma (n  21, overall survival 
15 months, CR  0%).15 No validated biomarkers exist to
predict response to chemotherapy or radiation. Topoisomer-
ase 2-alpha protein overexpression, detected in four of 14
cases of thymic carcinoma and of one of 15 type B3 thy-
moma, was reported to predict response to cyclophospha-
mide, adriamycin, cisplatin (CAP) chemotherapy (cyclophos-
phamide, adriamycin, cisplatin), whereas HER2/neu or
topoisomerase 2-alpha gene amplification and expression of
ERCC1 or thymidylate synthase did not.17 Thymoma tumor
specimens compared with normal thymus tissue have higher
mRNA levels of thymidylate synthase (which correlates with
resistance to 5-fluorouracil) and elevated dihydropyrimidine
dehydrogenase (which degrades 5-flurouracil), but this did
not correlate with clinicopathologic factors.18
MOLECULARLY TARGETED AGENTS
Epidermal Growth Factor Receptor Inhibitors
Epidermal growth factor receptor (EGFR) is overex-
pressed in thymomas and thymic carcinomas. EGFR gene am-
plification by fluorescence in situ hybridization (FISH) was
detected by Ionescu et al.19 in 30% of 32 cases of thymoma,
particularly in type B3 and thymic carcinomas. EGFR amplifi-
cation and polysomy were associated with more advanced stage
and capsule invasion.19 EGFR protein overexpression by immu-
nohistochemistry is present in 46 to 85% of thymomas.19–22 In a
Japanese series of 38 thymoma cases, EGFR protein over-
expression was associated with more advanced invasive
thymomas.20 However, Ionescu et al.19 detected EGFR
protein overexpression in 69% of cases and did not find an
association with clinicopathologic features. Somatic acti-
vating EGFR mutations have not been detected in a total of
129 thymomas collectively analyzed.6,20,22–24 Interestingly,
EGFR mutations have been observed in a Japanese series
in two of 29 thymomas (both L858R and G863D missense
mutations in exons 21) and zero of nine thymic carcino-
mas.25 The only report of an EGFR mutation in thymic
carcinoma is a single case report of a 29-year-old Japanese
woman with thymic carcinoma harboring a G719A in exon
18 and L858R in exon 21 detected by polymerase chain
reaction-restriction fragment length polymorphism method
who was treated with gefitinib (Table 2).26
The EGFR-tyrosine kinase inhibitors, gefitinib and
erlotinib, have produced minimal objective responses in
thymoma. A phase II study of gefitinib 250 mg daily in 26
patients with previously treated, advanced thymoma or
thymic carcinoma revealed only one PR, 15 patients with
stable disease (SD), and no CR.23 DNA sequencing from
five patients (including 1 PR) revealed no mutations in
EGFR exons 18 to 21 or KRAS exon 2.23 Erlotinib pro-
duced a clinical response in a female patient with myas-
thenia gravis and recurrent stage IV, malignant mixed
thymoma with tumor biopsies confirming EGFR overex-
pression by immunohistochemistry (IHC) but no EGFR
amplification or mutations.24
Cetuximab, a monoclonal antibody to EGFR, produced
a prolonged PR (12 months) and symptom benefit in a
single patient with advanced B2-type thymoma strongly ex-
pressing EGFR (IHC), who had previously received CAP
(cisplatin, doxorubicin, and cyclophosphamide) chemother-
apy and octreotide and prednisone.27 No EGFR amplification
or mutation was detected.27 Another case report of two
heavily pretreated patients with metastatic thymoma express-
ing EGFR by IHC reported PR after 3 months of therapy.28
Further evaluation of EGFR inhibition strategies,
particularly in tumors with EGFR overexpression by IHC,
is of great interest. A phase II trial of neoadjuvant cisp-
latin, doxorubicin, cyclophosphamide chemotherapy, and
cetuximab in locally advanced thymoma is underway
(NCT01025089). It is unclear whether KRAS mutations
affect response to cetuximab in thymoma. The lack of
activating EGFR mutations in thymoma supports the minimal
benefit demonstrated from current EGFR tyrosine kinase
inhibitors.
TABLE 1. Major Prospective Chemotherapy Trials in Stage III, IV Invasive Thymoma
Author No. of Patients Chemotherapy Regimen Response Rate, % Median Survival (mo)
Platinum-based chemotherapy
with anthracycline
Berruti et al.10 16 Cisplatin, doxorubicin, vincristine,
cyclophosphamide (ADOC)a
81 48
Kim et al.11 22 Cyclophosphamide, doxorubicin,
cisplatin, predinisone (CAPP)a
77 95% at 5 yr (median not reached)





Giaccone et al.13 16 Cisplatin, etoposide 56 51.6
Loehrer et al.14 28 (8 TC) Cisplatin, ifosfamide, etoposide (VIP) 35 31.6
Lemma et al.15 24 Carboplatin, paclitaxel 33 60
Nonplatinum chemotherapy
Loehrer et al.16 27 (11 TC) Pemetrexed alone 17 NR
a Chemotherapy administered as part of multimodality treatment with surgery and radiation.
TC, thymic carcinoma; NR, not reported.
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HER2
HER2/neu immunohistochemical protein overexpres-
sion is infrequent in thymoma.29 In thymic carcinoma, HER2/
neu immunohistochemical overexpression is present in 53%
of cases (9/17); however, no cases of HER2 gene amplifica-
tion by FISH were detected.29 Hence, therapies targeting
HER2 have remained unexplored to date.
RAS
Ras mutations have been detected in three of 62 thymic
tumors collectively analyzed6,23,24,30: one thymic carcinoma
and one B2-type thymoma harbored KRAS mutations (G12V
and G12A respectively),6 and one A-type thymoma harbored
an HRAS mutation (G13V).6 EGFR expression was high in
the KRAS-mutant tumors and moderate in the HRAS-mutant
tumor.6 KRAS mutations may predict for primary resistance
to EGFR tyrosine kinase inhibitors in lung cancer and resis-
tance to cetuximab in colorectal cancer. Therefore, clinical
trials with EGFR inhibitors in thymoma should evaluate Ras
mutation status.
KIT Inhibitors
KIT immunostaining is rare in thymomas (0–5%). In
contrast, KIT immunostaining is present in about 80% of
thymic carcinomas and represents a potential target for KIT
tyrosine kinase receptor inhibitors.21,31,32 KIT mutations were
present in five of 151 thymic tumors collectively analyzed, all
of which occurred only in thymic carcinomas.6,25,32–37 Girard
et al.6 reported a KIT mutation frequency of 4.4% (2 of 45
tumors) and found a mutant form harboring V560 deletion in
exon 14, which is associated with sensitivity to imatinib, and
another KIT mutant with a novel KIT H697Y mutation in
exon 14, which is associated in vitro with greater sensitivity
to sunitinib versus imatinib.
Imatinib is an oral multikinase inhibitor of KIT, Bcr-
Abl, and PDGFR. An objective response to imatinib was first
reported in a patient with metastatic thymic carcinoma over-
expressing KIT and harboring an activating V560del KIT
mutation.33 A pilot study of second-line imatinib 600 mg
daily in 11 patients with advanced thymic carcinoma and KIT
positive (n  9) or PDGFR positive (n  2) by IHC reported
no objective responses, three patients achieved SD for a
median duration of 6 weeks.38 A phase II study of seven
patients with unresectable WHO B3 or C thymoma also
reported no responses (two patients had SD and five patients
had progression); however, there were no activating KIT
mutations or PDGFR mutations detected in five patients with
available mutational analysis.36
Dasatinib is an oral multikinase inhibitor of KIT, Bcr-
Abl, PDGFR, and Src family kinases and has demonstrated
responses in imatinib-resistant BCR-ABL positive leukemias.
A PR to dasatainib 140 mg/d, has been documented in a
patient with a Masaoka stage I, B2-type thymoma that was
EGFR positive (IHC and FISH) and KIT negative (IHC),
suggesting that non-KIT-targeted inhibition of Src kinases by
dasatinib may be important.35
Sorafenib, an oral multikinase inhibitor of KIT,
VEGFR, PDGFR, and BRAF, resulted in a PR in a heavily
pretreated patient with metastatic thymic carcinoma harbor-
ing a KIT missense mutation on exon 17 (D820E).37 Another
recent case report of response to sorafenib exists in a 46-year-
old man with metastatic platinum resistant thymic carcinoma
expressing KIT (CD 117) and VEGF.39
TABLE 2. Molecularly Targeted Agents
Class Agent Mechanism
EGFR inhibitors Cetuximab Recombinant, chimeric monoclonal antibody directed against the EGFR. Binds to the
extracellular domain of the EGFR, thereby preventing receptor activation and signal
transduction.
Gefitinib, Erlotinib Small-molecule tyrosine kinase inhibitor of the EGFR. Competes with the binding of ATP
to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation
and resulting in inhibition of signal transduction.
KIT inhibitor Imatinib Small-molecule multi-kinase inhibitor of KIT, Bcr-Abl, and PDGFR.
Dasatinib Small-molecule multi-kinase inhibitor of KIT, Bcr-Abl, PDGFR, and Src family kinases.
Sorafenib Small-molecule multi-kinase inhibitor of Raf kinases, KIT, VEGFR, and PDGFR.
HDAC inhibitor Belinostat Inhibitor of HDAC class I and II enzymes, thereby inhibiting tumor cell proliferation,
inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis.
VEGF inhibitor Bevacizumab Recombinant humanized monoclonal antibody directed against the VEGF, a pro-
angiogenic cytokine. Inhibits VEGF receptor binding, thereby preventing growth and
maintenance of tumor blood vessels.
IGF-1R inhibitor Cixutumumab (IMC-A12) Fully human IgG1 monoclonal antibody directed against IGF-1R. Prevents binding of the
natural ligand IGF-1 and subsequent activation of PI3K/AKT signaling pathway.
DNMTis Decitabine Cytidine antimetabolite analogue, which incorporates into DNA and inhibits DNA
methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of
DNA replication.
CDK/TRKA inhibitor PHA-848125AC Inhibits CDK2, CDK1, CDK4, and TRKA, and thus may result in cell cycle arrest and
apoptosis.
EGFR, epidermal growth factor receptor; HDAC, hydroxamic acid-type histone deacetylase; VEGF, vascular endothelial growth factor; IGF-1R, insulin-like growth factor-1
receptor; DNMTis, DNA methyltransferase inhibitors; CDK, cyclin-dependent kinase; TRKA, thropomyosin receptor kinase A.
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KIT remains an interesting therapeutic target in thymic
carcinomas and activating mutations although rare, warrant
further prospective evaluation in trials with KIT inhibitors as
they seem to be associated with response to imatinib. KIT
protein expression does not seem to be associated with
response to KIT inhibitors. Further evaluation of combined
inhibition of KIT and Src family kinases may be warranted.
Histone Deacetylase Inhibitor
Histone deacetylase (HDAC) enzymes catalyze the
removal of an acetyl group from the terminal lysine residues
of histone proteins, leading to more compact chromatin and
repression of associated genes. Belinostat, an inhibitor of
HDAC class I and II enzymes, demonstrated tumor shrinkage
and SD for 17 months in a patient with thymoma in the first
in human trial.40 Belinostat has demonstrated some activity in
a phase II study of 32 patients with recurrent or metastatic
thymoma and thymic carcinoma.41 Of 27 evaluable patients,
two patients had a PR, 15 had SD, and 10 had progression,
but no responses were seen in patients with thymic carcino-
mas.41 An increase in protein acetylation in PBMCs was
observed in all patients analyzed. A phase I/II study of
first-line belinostat in combination with cisplatin, doxorubi-
cin, and cyclophosphamide in advanced or recurrent thy-
moma is underway (NCT01100944). The first in human study
of another HDAC inhibitor, 4SC-201, also demonstrated
activity in a patient with thymoma with marginal response
beyond 6 months.42
VEGF Inhibitor
VEGF-A and VEGFR-1 and -2 are expressed in both
normal and malignant thymic tissue.43 Bevazicumab (15
mg/kg q3 weeks) combined with erlotinib (150 mg/d) has
demonstrated limited activity in a phase II trial of 18 patients
with refractory thymoma (n  11) and thymic carcinoma
(n  7).44 Although well tolerated, there were no CR, 11
patients achieved SD (60%) and seven had PD.44 A phase I
study of aflibercept, a soluble decoy receptor that binds
VEGF-A, and docetaxel 75 mg/m2, demonstrated a PR in a
patient with thymoma.45 In a phase IB study of motesanib, an
oral VEGFR-1, -2, -3, KIT, and PDGFR inhibitor, a patient
with chemotherapy-refractory thymoma achieved tumor
shrinkage after 39 weeks on therapy.46
Insulin-Like Growth Factor-1 Receptor Inhibitor
The insulin-like growth factor-1 receptor (IGF-1R) is
found in thymic tumors and thought to play an important role
in tumorigenicity. A multicenter phase II study of IMC-A12,
an IGF-1R inhibitor, in advanced platinum-refractory thy-
moma and thymic carcinoma is underway (NCT00965250).
DNA Methyltransferase Inhibitors
Decitabine was developed as a cytotoxic agent to treat
leukemia at high doses, but at lower doses over longer
duration, DNA methyltransferase inhibitors are predomi-
nantly epigenetic modulating. Decitabine inhibits DNMT,
induces global DNA hypomethylation and increases expres-
sion of specific genes. In a phase I study of decitabine in 31
patients with refractory solid tumors, one of four patients
with thymoma had a PR.47
Cyclin-Dependent Kinases/Thropomyosin
Receptor Kinase A Inhibitor
Cyclin-dependent kinases (CDK) are serine/threonine
kinases involved in regulation of the cell cycle. Thropomyo-
sin receptor kinase A (TRKA) is a neurotrophin receptor that
is mutated in several cancer types. Inhibition of CDKs and
TRKA may result in cell cycle arrest and apoptosis of tumor
cells that express these kinases. A phase II study in advanced
thymic carcinoma of PHA-848125AC, an oral CDK inhibitor
and TRKA inhibitor, is underway (NCT01011439).
SUMMARY
Improved understanding of molecular characteristics of
thymomamay facilitate greater accuracy in disease classification
and application of novel targeted therapies. Advances in molec-
ular understanding and clinical research in thymoma have been
limited due to the rarity and heterogeneity of this disease and
evolving multidisciplinary treatment approaches. Discovery of
clinically important biomarkers is difficult due to the limited
statistical power of small case series in the literature. A desperate
need exists for prospective collaborative research efforts to
obtain statistically significant findings. Future research questions
remain as to whether we can use biomarkers to identify patients
with stage II or III disease who do not require adjuvant therapy
and to determine the optimal strategy for testing single or
combined targeted therapies alone or with chemotherapy in the
advanced or locally advanced disease. Chemotherapeutic agents
with the most activity include cisplatin and doxorubicin. Tar-
geted agents offer less toxicity, but several phase II trials have
failed to demonstrate responses in advanced disease; EGFR
inhibition with gefitinib in unselected patients, KIT inhibition
with imatinib in patients without KIT mutations, VEGF inhibi-
tion with bevacizumab in unselected patients, and HDAC inhi-
bition with belinostat in unselected patients. This suggests that
the success of clinical trials using targeted therapies requires
greater attention to tumor specimen collection and extensive
molecular profiling to facilitate patient enrichment strategies to
improve response rates, confirm proof of principle, and identify
potential mechanisms of sensitivity and resistance. In thymoma,
cetuximab may have efficacy particularly in thymomas with
EGFR overexpression; while in thymic carcinoma, KIT inhibi-
tors remain promising agents in those with KIT mutations. In
such a rare tumor, creative models to guide targeted therapies
based on molecular signatures in tumor biopsies48 may help to
maximize efficacy of future clinical trials.
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